Zacks Investment Research cut shares of BioLineRx Ltd. (NASDAQ:BLRX) from a hold rating to a sell rating in a research report released on Thursday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Other equities research analysts have also recently issued reports about the stock. Maxim Group cut shares of BioLineRx from a buy rating to a hold rating and dropped their target price for the stock from $4.00 to $1.00 in a research report on Friday, August 12th. Roth Capital reaffirmed a buy rating and issued a $7.00 target price on shares of BioLineRx in a research report on Sunday, August 14th. Finally, S&P Equity Research dropped their target price on shares of BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.05 on Thursday. The company’s market capitalization is $59.24 million. The firm has a 50-day moving average of $1.06 and a 200-day moving average of $0.94. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.01. On average, equities analysts predict that BioLineRx will post ($0.28) earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. KCG Holdings Inc. raised its stake in BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock worth $174,000 after buying an additional 121,650 shares in the last quarter. Morgan Stanley raised its stake in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC raised its stake in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares in the last quarter. Institutional investors and hedge funds own 14.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/25/biolinerx-ltd-blrx-lowered-to-sell-at-zacks-investment-research.html.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.